Abstract

Introduction: distal renal tubular acidosis (dRTA) presents itself with variable clinical manifestations and often with late expressions that impact on prognosis.

Case report: A 45-day-old male infant was admitted with stopping growth, difficult feeding and vomiting after meals. Clinical tests and labs revealed a type 1 renal tubular acidosis, even if the first blood tests showed ammonium and lactate increase. We had to exclude metabolic diseases before having a certain diagnosis.

Conclusions: blood and urine investigations and genetic tests are fundamental to formulate dRTA diagnosis and to plan follow-up, according to possible phenotypic expressions of recessive and dominant autosomal forms in patients with dRTA.

Introduction

The term "renal tubular acidosis", first used by Pines and Mudge in 1951, identifies a group of disorders characterized by metabolic acidosis, secondary to bicarbonate tubular reabsorption defect and/or renal hydrogen ions secretion defect. Tubular acidosis is characterised by hyperchloremic metabolic acidosis with normal plasmatic anion gap and glomerular function substantially preserved. RTA may be primitive (genetic) or secondary to systemic pathologies or to drug and toxic substances intake.

Distal renal tubular acidosis (type 1 or dRTA) is caused by a deficient distal renal acidification mechanism. Primitive dRTA exists in three main variants, according to transport protein involvement and clinical presentation: autosomal dominant form and recessive form (that can occur with or without neurosensory hearing loss). Distal renal tubular acidosis presents itself with variable severity of metabolic acidosis typically associated with hypokalemia, hypercalciuria and hypocitraturia. Rickets and osteomalacia can occur both in dominant and recessive forms. The former are generally milder and have a later onset in childhood and adulthood, the latter may arise over the first few months of life with stopping growth. Nephrocalcinosis and nephrolithiasis are frequent. Recessive forms may show neurosensory hearing loss that can be present since the early months of life or later until adulthood.

As described later on, clinical manifestations and the prognosis of the genetic form of dRTA are related both to the gene involved and the mutation type. Diagnosis of distal renal tubular acidosis is confirmed by urine alkalinity within a systemic metabolic acidosis framework. Treatment with oral bicarbonate and/or citrate is able to correct metabolic acidosis, bone abnormalities and impaired growth, but is not effective in modifying or preventing neurosensory hearing loss. Aside from complete forms of dRTA, the so called "incomplete" forms (i.dRTA), characterized by a distal urine acidification deficit, albeit without systemic metabolic acidosis, are becoming increasingly common. In these forms, which may manifest themselves as recurrent nephrolithiasis, rickets resistance to therapy, growth deficit, the distal tubular defect is shown by the absence of urine acidification (pH < 5.5) after oral load of ammonium chloride.

Case report

A 45-day-old infant was referred to our clinic from the attending pediatrician for stopping growth. He was born at term, by caesarean section for breech presentation. Apgar score, at the first
minute, was 8, then 10 at the fifth minute. Weight at birth was 2.950 Kg. Over two weeks of life he received artificial feeding and his weight upon hospitalization was 3.150 Kg (post-natal growth of 190 g). Parents reported that their baby fed with difficulty and sporadically presented vomiting after meals. He was admitted in bad general conditions with adipose and muscular mass scant trophism, reduced skin turgescence and elasticity, accompanied by modest plagiocephaly. Anterior fontanelle was normal, with intact sensory functions and absence of hyporeactivity or meningeal signs.

Upon hospitalization, CBC didn’t show any significant alterations, whereas a few days later we noticed the appearance of hypochromic anemia. Blood glucose level was normal (3.9 mmol/L), liver and kidney functions were preserved. Inflammatory indicators were negative, and blood tests showed hypokalemia (2.6 mmol/L), hyperchloremia (up to 117 mmol/L), normal natremia (139 mmol/L), hypercalcaemia (3.05 mmol/L) and a phosphate value of 2.38 mmol/L. At first, blood-gas analysis showed a metabolic acidosis with pH 7.25, HCO₃⁻ 31.3 mmol/l, EB -14.4 and 16.4 mmol/L of anion gap [(Na⁺ - (Cl⁻ + HCO₃⁻)]

Urine tests detected modest proteinuria, leukocyturia and hemoglobin traces, urinary pH was 7 and sediment presented several amorphous phosphate granules in addition to various exfoliation epithelial cells.

Urine culture was negative. Some urine electrolytes were modestly increased such as natriuria and kaliuria, while hypercalciuria was quite high (calcium/creatinine ratio 0.97).

An increase in lactate (7.5 mmol/L) and hyperammonemia (66 (µmol/l) was noted, which made us suspect the presence of an underlying metabolic disease.

However, urine organic acids, urinary amino acids, blood amino acids, and pyruvate showed no significant alterations for diagnosis. Transfontanellar and gastroesophageal ultrasonography were normal, while renal ultrasonography showed a marked increase of echogenicity, completely covering all renal pyramids, attributable to medullary nephrocalcinosis (Fig. 1). Slit lamp examination revealed transparent lens and cornea; besides, the eye ground was normal. Audiometric screening (accuscreen) seemed to be negative. Since our patient was strongly considered to have a distal renal tubular acidosis owing to impaired growth, growth retardation, and blood alterations, we planned genetic investigations in order to find the mutation type responsible for clinical signs. Additionally, we ordered a corrective treatment with intravenous paediatric hydration (dextrose 5% and sodium bicarbonate) and KCl, followed by oral therapy with sodium bicarbonate (3 mmol/Kg/day) and potassium citrate (equivalent to 2 mmol/Kg/day tripotassium citrate monohydrate) that determined an improvement of blood values and general conditions (resumption of growth and increase in weight).

Moreover our patient received iron therapy for sideropenic anaemia and gastroprotective drugs for regurgitation associated with potassium therapy. Sodium and potassium citrate doses were constantly changed during follow-up according to clinical needs, electrolytic modifications and auxological indices.

<table>
<thead>
<tr>
<th>Tab. 1</th>
<th>INHERITED FORMS OF DISTAL RENAL TUBULAR ACIDOSIS . MODIFIED BY6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inheritance</td>
<td>Age at presentation</td>
</tr>
<tr>
<td>Dominant</td>
<td>Older /Adult</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Recessive</td>
<td>Childhood</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Recessive with early onset hearing loss</td>
<td>Infancy/Childhood</td>
</tr>
<tr>
<td>Recessive with late onset hearing loss</td>
<td>Infancy/Childhood</td>
</tr>
</tbody>
</table>
We observed that the need for bicarbonate - as well as potassium citrate - had halved over time compared to the initial doses (fig. 2). Upon the last control (8 months), the baby weighed 6.950 Kg and the metabolic balance was preserved.

**Discussion**

Molecular genetic investigations performed in the families of patients with dRTA allowed for a better understanding of the physiological mechanism of urine acidification and defined genotype-phenotype correlation in different distal renal tubular acidosis forms (tab 1). Autosomal dominant dRTA is caused by mutations affecting the exchange Cl⁻/HCO₃⁻ AE1, encoded by SLC4A1 gene. This protein is mainly expressed in erythrocytes (eAE1) and in kidneys (kAE1). Even if these forms of distal tubular acidosis present themselves with common distal acidosis, they usually occur in late adolescence or adulthood, and with a milder clinical history compared to autosomal recessive forms (connected to mutations of H⁺/ATPase). These recessive forms have an early onset, (often during the first month of life), in the first or the second childhood with metabolic acidosis, hypokalemia, stopping growth, hypercalciuria and nephrocalcinosis. They cause rickets and stopping growth, that may lead to renal failure, if untreated or wrongly treated. An important prognostic element is the possible association with neurosensory hearing loss (NSHL).

Autosomal recessive dRTA were associated with H⁺/ATPase B1 and A4 subunit mutations. Subunit B1 is coded by ATP6V1B1 gene located on chromosome 2q13. This protein is expressed in cochlear cells and in endolymphatic SAC, where it contributes to the maintenance of endolymphatic acid pH. Several mutations altering the structure or abolishing the production of B1 subunit, with irreversible cochlear cell damage, were identified. 70-90% of patients with mutations of this subunit showed NSHL onset (within the tenth year of life). H⁺/ATPase A4 subunit is coded by ATP6V0A4 gene, located on chromosome 7 p33-34.

A recent study, carried out on 43 dRTA patients, showed that these protein mutations were associated with early NSHL onset in about 40% of patients. Therefore, unlike previous conclusions, the finding of A4 subunit dRTA mutation doesn’t exclude the possibility of NSHL onset (even within the tenth year of life), thereby reconsidering the role of genetic investigations in early prognosis. The case presented had a very early onset with feeding difficulties and significant slowdown in growth since the early weeks of life, as demonstrated by the low weight increase (only 190 grams in 45 days). Upon onset, the metabolic acidosis was severe on average, associated with hypokalemia, hypercalciuria and bilateral nephrocalcinosis. Important signs were hypercalcemia and hyperphosphorhemia, both plausible expression of bone mineral reabsorption, along with hyperammonemia, as already reported in other cases, due to ammonium ion deficient excretion. 

Anion gap was slightly increased (~ 16 mmol/L) and this characteristic, which is not typical of dRTA, was probably caused by a transient hyperlactacidemia. Upon hospitalization, lactate concentration was 7.5 mmol/L compatible with a severe dehydration and mild systemic hypoperfusion. However, we had to consider the possibility of an underlying metabolic disease. The normality of lactate/pyruvate ratio, the absence of significant alterations of urine
organic acids, urinary amino acids, blood amino acids made us rule out a metabolic disorder. Persistently elevated pH urinary values (7.5) despite systemic metabolic acidosis, lead us to the diagnosis of an early-onset distal renal tubular acidosis. Treatment with sodium bicarbonate and potassium citrate has promptly corrected metabolic acidosis, hypokalemia and hypercalciuria (Fig. 2a). Our patient presented a speedy recovery of weight and impaired growth, while alkali needs (calculated pro Kg of body weight) that was required to maintain metabolic balance, were gradually reduced during the first 9 months of treatment (Fig. 2b).

Conclusions

Negativity of audiometric screening leads us to exclude, until now, the involvement of the inner ear. For the future, it will be extremely important, whatever the results of genetic investigations might be, to schedule a regular follow-up with methodologies in line with the age of patients, in order to detect the first signs of a neurosensory hearing loss, which is key for the prognosis.

References